Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 500-500
10.1200/jco.2014.32.15_suppl.500